Literature DB >> 19758696

FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).

Hideki Makishima1, Manjot Rataul, Lukasz P Gondek, Jungwon Huh, James R Cook, Karl S Theil, Mikkael A Sekeres, Elizabeth Kuczkowski, Christine O'Keefe, Jaroslaw P Maciejewski.   

Abstract

Cytogenetic aberrations identified by metaphase cytogenetics (MC) have important diagnostic, prognostic and therapeutic roles in myelodysplastic syndromes (MDS). Fluorescence in situ hybridization (FISH) complements MC by the ability to evaluate large numbers of both interphase and metaphase nuclei. However, clinically practical FISH strategies are limited to detection of known lesions. Single nucleotide polymorphism array (SNP-A)-based karyotyping can reveal unbalanced defects with superior resolution over MC and FISH and identify segmental uniparental disomy (UPD) undetectable by either method. Using a standardized approach, we focused our investigation on detection of -5/del(5q), -7/del(7q), trisomy 8 and del(20q) in patients with MDS (N=52), MDS/myeloproliferative overlap syndromes (N=7) and acute myeloid leukemia (N=15) using MC, FISH and SNP-A karyotyping. The detection rate for del(5q) was 30, 32 and 32% by MC, FISH, and SNP-A, respectively. No single method detected all defects, and detection rates improved when all methods were used. The rate for detection of del(5q) increased incrementally to 35% (MC+FISH), 38% (MC+SNP-A), 38% (FISH+SNP-A) and 39% (all three methods). Similar findings were observed for -7/del(7q), trisomy 8 and -20/del(20q). We conclude that MC, FISH and SNP-A are complementary techniques that, when applied and interpreted together, can improve the diagnostic yield for identifying genetic lesions in MDS and contribute to the better description of abnormal karyotypes. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19758696      PMCID: PMC2826525          DOI: 10.1016/j.leukres.2009.08.023

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

Review 1.  Whole genome scanning as a cytogenetic tool in hematologic malignancies.

Authors:  Jaroslaw P Maciejewski; Ghulam J Mufti
Journal:  Blood       Date:  2008-05-27       Impact factor: 22.113

2.  Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens.

Authors:  R B Jenkins; M M Le Beau; W J Kraker; T J Borell; P G Stalboerger; E M Davis; L Penland; A Fernald; R Espinosa; D J Schaid
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

3.  Detection and monitoring of trisomy 8 by fluorescence in situ hybridization in acute myeloid leukemia: a multicentric study.

Authors:  A Cuneo; R Bigoni; M G Roberti; A Bardi; G M Rigolin; N Piva; M Mancini; M Nanni; G Alimena; C Mecucci; C Matteucci; R La Starza; P Bernasconi; P Cavigliano; E Genini; A Zaccaria; N Testoni; C Carboni; G Castoldi
Journal:  Haematologica       Date:  1998-01       Impact factor: 9.941

4.  Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.

Authors:  Christina Evers; Manfred Beier; Anne Poelitz; Barbara Hildebrandt; Kati Servan; Matthias Drechsler; Ulrich Germing; Hans-Dieter Royer; Brigitte Royer-Pokora
Journal:  Genes Chromosomes Cancer       Date:  2007-12       Impact factor: 5.006

5.  Fluorescence in situ hybridization improves the detection of monosomy 7 in myelodysplastic syndromes.

Authors:  M Flactif; J L Lai; C Preudhomme; P Fenaux
Journal:  Leukemia       Date:  1994-06       Impact factor: 11.528

6.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.

Authors:  Lukasz P Gondek; Ramon Tiu; Christine L O'Keefe; Mikkael A Sekeres; Karl S Theil; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2007-10-22       Impact factor: 22.113

7.  High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration.

Authors:  K Paulsson; M Heidenblad; B Strömbeck; J Staaf; G Jönsson; A Borg; T Fioretos; B Johansson
Journal:  Leukemia       Date:  2006-05       Impact factor: 11.528

Review 8.  Chromosomal deletions in the myelodysplastic syndrome.

Authors:  G J Mufti
Journal:  Leuk Res       Date:  1992       Impact factor: 3.156

Review 9.  Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes.

Authors:  R Tiu; L Gondek; C O'Keefe; J P Maciejewski
Journal:  Leukemia       Date:  2007-06-07       Impact factor: 11.528

10.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.

Authors:  P Morel; M Hebbar; J L Lai; A Duhamel; C Preudhomme; E Wattel; F Bauters; P Fenaux
Journal:  Leukemia       Date:  1993-09       Impact factor: 11.528

View more
  14 in total

1.  Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis.

Authors:  Kathy L McGraw; Chia-Ho Cheng; Y Ann Chen; Hsin-An Hou; Björn Nilsson; Giulio Genovese; Thomas Cluzeau; Andrea Pellagatti; Bartlomiej P Przychodzen; Mar Mallo; Leonor Arenillas; Azim Mohamedali; Lionel Adès; David A Sallman; Eric Padron; Lubomir Sokol; Chimene Moreilhon; Sophie Raynaud; Hwei-Fang Tien; Jacqueline Boultwood; Benjamin L Ebert; Francesc Sole; Pierre Fenaux; Ghulam J Mufti; Jaroslaw P Maciejewski; Peter A Kanetsky; Alan F List
Journal:  Blood Adv       Date:  2019-11-26

2.  Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.

Authors:  Tetsuichi Yoshizato; Yasuhito Nannya; Yoshiko Atsuta; Yusuke Shiozawa; Yuka Iijima-Yamashita; Kenichi Yoshida; Yuichi Shiraishi; Hiromichi Suzuki; Yasunobu Nagata; Yusuke Sato; Nobuyuki Kakiuchi; Keitaro Matsuo; Makoto Onizuka; Keisuke Kataoka; Kenichi Chiba; Hiroko Tanaka; Hiroo Ueno; Masahiro M Nakagawa; Bartlomiej Przychodzen; Claudia Haferlach; Wolfgang Kern; Kosuke Aoki; Hidehiro Itonaga; Yoshinobu Kanda; Mikkael A Sekeres; Jaroslaw P Maciejewski; Torsten Haferlach; Yasushi Miyazaki; Keizo Horibe; Masashi Sanada; Satoru Miyano; Hideki Makishima; Seishi Ogawa
Journal:  Blood       Date:  2017-02-21       Impact factor: 22.113

Review 3.  The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?

Authors:  Zaher K Otrock; Ramon V Tiu; Jaroslaw P Maciejewski; Mikkael A Sekeres
Journal:  Expert Rev Hematol       Date:  2013-02       Impact factor: 2.929

4.  Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.

Authors:  Sara A Monaghan; Lijun Dai; Markus Y Mapara; Daniel P Normolle; Susanne M Gollin; Suzanne Lentzsch
Journal:  Leuk Lymphoma       Date:  2013-01-28

5.  Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Vu H Duong; Rami S Komrokji; Alan F List
Journal:  Ther Adv Hematol       Date:  2012-04

6.  Evaluation of the utility of peripheral blood vs bone marrow in karyotype and fluorescence in situ hybridization for myelodysplastic syndrome diagnosis.

Authors:  Zhaleh Asadi Fakhr; Valiollah Mehrzad; Amin Izaditabar; Mansoor Salehi
Journal:  J Clin Lab Anal       Date:  2018-06-11       Impact factor: 2.352

Review 7.  There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.

Authors:  Amer M Zeidan; Rami S Komrokji
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

8.  DOCK4 deletion at 7q31.1 in a de novo acute myeloid leukemia with a normal karyotype.

Authors:  Eigil Kjeldsen; Christopher Veigaard
Journal:  Cell Oncol (Dordr)       Date:  2013-08-27       Impact factor: 6.730

9.  Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.

Authors:  Yuka Sugimoto; Mikkael A Sekeres; Hideki Makishima; Fabiola Traina; Valeria Visconte; Anna Jankowska; Andres Jerez; Hadrian Szpurka; Christine L O'Keefe; Kathryn Guinta; Manuel Afable; Ramon Tiu; Kathy L McGraw; Alan F List; Jaroslaw Maciejewski
Journal:  J Hematol Oncol       Date:  2012-03-05       Impact factor: 17.388

10.  CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

Authors:  Hideki Makishima; Anna M Jankowska; Michael A McDevitt; Christine O'Keefe; Simon Dujardin; Heather Cazzolli; Bartlomiej Przychodzen; Courtney Prince; John Nicoll; Harish Siddaiah; Mohammed Shaik; Hadrian Szpurka; Eric Hsi; Anjali Advani; Ronald Paquette; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-02-23       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.